Click on a filter below to refine your search. Remove a filter to broaden your search.
Baricitinib plus remdesivir was linked to a reduced risk of death and progression to invasive mechanical ventilation.
Severely immunocompromised individuals had greater SARS-CoV-2 evolution and a higher risk for developing resistance against therapeutic mAbs.
Female sex and previous mental health disorders and asthma were associated with long COVID, regardless of COVID-19 severity.
Physical, psychiatric and cognitive problems were seen in those discharged to long-term acute care hospitals.
Symptoms were linked to increased odds of at least moderate interference with functioning and lower odds of full-time employment.
The posthospitalization prevalence of residual lung abnormalities was estimated at 11.7% in sensitivity analyses.
Changes include a new section relating to COVID-19 vaccines and the addition of a newly licensed vaccine for hepatitis B.
No significant reduction was seen in the percent of patients with urgent care or emergency department visits or hospitalization.
Vaccine hesitancy varied considerably; 12.1% of vaccinated individuals were hesitant about booster doses.
Molnupiravir and nirmatrelvir-ritonavir combination therapy should be considered for patients within five days of symptom onset.